MINI FUTURE OPTIONSSCHEIN PUT - GILEAD SCIENCES | Market Closed - Boerse Frankfurt Warrants 01:04:47 18/05/2024 am IST | ||
| 4.93 EUR | +0.41% |
|
| Current month | -5.74% | ||
| 1 month | -2.18% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
GILEAD SCIENCES, INC.
Latest news about GILEAD SCIENCES, INC.
More news
| Date | Price | Change |
|---|---|---|
| 17/24/17 | 4.93 | +0.41% |
| 16/24/16 | 4.91 | -0.81% |
| 15/24/15 | 4.95 | +0.41% |
| 14/24/14 | 4.93 | -1.00% |
| 13/24/13 | 4.98 | -2.54% |
Real-time Boerse Frankfurt Warrants
Last update May 18, 2024 at 01:04 am IST
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | GILEAD SCIENCES, INC. |
| Issuer | DZ BANK |
| WKN | DJ7N7D |
| ISIN | DE000DJ7N7D6 |
| Date issued | 15/12/2023 |
| Strike | 121 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 3.559 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 5.29 € |
|---|---|
| Lowest since issue | 3.08 € |
Company Profile
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows:
- sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV);
- other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products.
Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).
Sector
-
Consensus: Gilead Sciences, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
67.72
USD
Average target price
82.93
USD
Spread / Average Target
+22.46%
- Stock Market
- Certificates
- Certificat